




FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

STEVEN L. HIGHLANDER
PARTNER
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3184
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

October 23, 2003

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:	
October 23, 2003	
Date	

MS DD
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/644,659 entitled "STARS - A MUSCLE-SPECIFIC ACTIN-BINDING PROTEIN" – Eric Olson and Akiko Arai*
Our reference: MYOG:037US
Client reference: UTSD:0906


Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references C1-C15.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/MYOG:037US.


Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,


Steven L. Highlander
Reg. No. 37,642

SLH/kmv
Encl.: as noted

25349436.1



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Eric Olson
Akiko Arai

Serial No.: 10/644,659


Filed: August 20, 2003

For: STARS - A MUSCLE-SPECIFIC ACTIN-
BINDING PROTEIN

Group Art Unit: Unknown

Examiner: Unknown

Atty. Dkt. No.: MYOG:037US

CERTIFICATE OF MAILING 37 C.F.R. 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below.	
October 23, 2003	
Date	

INFORMATION DISCLOSURE STATEMENT

MS DD

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be

an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/MYOG:037US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: October 23, 2003

Form PTO-1449 (modified)

Atty. Docket No.

MYOG:037US

Serial No.

10/644,659

List of Patents and Publications for Applicant's

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Applicant

Eric Olson and Akiko Arai

Filing Date:

August 20, 2003

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 1

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Belaguli <i>et al.</i> , "Cardiac tissue enriched factors serum response factor and GATA-4 are mutual coregulators," <i>Molecular and Cellular Biology</i> , 20(20):7550-7558, 2000.
	C2	Chen and Schwartz, "Recruitment of the tinman homolog Nkx-2.5 by serum response factor activates cardiac α -actin gene transcription," <i>Molecular and Cellular Biology</i> , 16(11):6372-6384, 1996.
	C3	Cooper and Schafer, "Control of actin assembly and disassembly at filament ends," <i>Curr. Opin. Cell. Biol.</i> , 12:97-103, 2000.
	C4	Kaibuchi <i>et al.</i> , "Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells," <i>Annu. Rev. Biochem.</i> , 68:459-486, 1999.
	C5	Mack <i>et al.</i> , "Smooth muscle differentiation marker gene expression is regulated by RhoA-mediated actin polymerization," <i>J. Biol. Chem.</i> , 276(1):341-347, 2001.
	C6	Maekawa <i>et al.</i> , "Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase," <i>Sciences</i> , 285:895-898, 1999.
	C7	Morin <i>et al.</i> , "Serum response factor-GATA ternary complex required for nuclear signaling by a G-protein-coupled receptor," <i>Molecular and Cellular Biology</i> , 21(4):1036-1044, 2001.
	C8	Morton <i>et al.</i> , "Lantrunculin alters the actin-monomer subunit interface to prevent polymerization," <i>Nat. Cell. Biol.</i> , 2:376-378, 2000.


25336606.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)



Form PTO-1449 (modified)

Atty. Docket No.
MYOG:037USSerial No.
10/644,659

List of Patents and Publications for Applicant's

Applicant
Eric Olson and Akiko Arai

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
August 20, 2003Group:
UnknownU.S. Patent Documents
See Page 1Foreign Patent Documents
See Page 1Other Art
See Page 1

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Narumiya <i>et al.</i> , "Rho effectors and reorganization of actin cytoskeleton," <i>FEBS Letters</i> , 410:68-72, 1997.
	C10	Sotiropoulos <i>et al.</i> , "Signal-regulated activation of serum response factor is mediated by changes in actin dynamics," <i>Cell</i> , 98:159-169, 1999.
	C11	Van Aelst and D'Souza-Schorey, "Rho GTPases and signaling networks," <i>Genes Dev.</i> , 11:2295-2322, 1997.
	C12	Wang <i>et al.</i> , "Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor," <i>Cell</i> , 105:851-862, 2001.
	C13	Wei <i>et al.</i> , "RhoA signaling via serum response factor plays an obligatory role in myogenic differentiation," <i>J. Biol. Chem.</i> , 273(46):30287-30294, 1998.
	C14	Wei <i>et al.</i> , "Beta1 integrin and organized actin filaments facilitate cardiomyocyte-specific RhoA-dependent activation of the skeletal alpha-actin promoter," <i>FASEB J.</i> , 785-796, 2001.
	C15	Yamamoto <i>et al.</i> , "Phosphatidylinositol 4,5-bisphosphated induces actin stress-fiber formation and inhibits membrane ruffling in CV1 cells," <i>J. Cell. Biol.</i> , 152(5):867-876, 2001.

25336606.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.